Craig C. Estwick
Vorsitzender bei Nexpep Pty Ltd.
Profil
Craig C.
Estwick currently works at Nexpep Pty Ltd., as Chairman from 2009.
Mr. Estwick also formerly worked at ImmusanT, Inc., as Director and Deloitte Consulting Pty Ltd., as Partner in 2000.
Mr. Estwick received his graduate degree in 2003 from The University of Queensland.
Aktive Positionen von Craig C. Estwick
| Unternehmen | Position | Beginn |
|---|---|---|
| Nexpep Pty Ltd. | Vorsitzender | 01.01.2009 |
Ehemalige bekannte Positionen von Craig C. Estwick
| Unternehmen | Position | Ende |
|---|---|---|
Deloitte Consulting Pty Ltd.
 Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Corporate Officer/Principal | 01.01.2000 |
ImmusanT, Inc.
 ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Craig C. Estwick
| The University of Queensland | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
ImmusanT, Inc.
ImmusanT, Inc. Medical SpecialtiesHealth Technology ImmusanT, Inc. develops a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Its Epitope-Specific Immuno-Therapy platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. The firm’s product Nexvax2, protects celiac disease patients against the debilitating effects of gluten. The company was by Leslie J. Williams and Robert P. Anderson founded in December 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Nexpep Pty Ltd. | |
Deloitte Consulting Pty Ltd.
Deloitte Consulting Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte Consulting Pty Ltd. provides cyber security consulting services. The company is based in Sydney, Australia. | Commercial Services |